Truist Securities Maintains Arcutis Biotherapeutics (ARQT) Buy Recommendation
27/5 02:51
Fintel reports that on May 26, 2023, Truist Securities maintained coverage of Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy recommendation....
|
|
|
27/5 02:51
Fintel reports that on May 26, 2023, Truist Securities maintained coverage of Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy recommendation....